Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
Bamias, A × Tzannis, K Beuselinck, Benoit Oudard, S Escudier, B Diosynopoulos, D Papazisis, K Lang, H Wolter, Pascal de Guillebon, E Stravodimos, K Chrisofos, M Fountzilas, G Elaidi, R-T Dimopoulos, M A Bamia, C #
British Journal of Cancer vol:109 issue:2 pages:332-41
Accurate prediction of outcome for metastatic renal cell carcinoma (mRCC) patients receiving targeted therapy is essential. Most of the available models have been developed in patients treated with cytokines, while most of them are fairly complex, including at least five factors. We developed and externally validated a simple model for overall survival (OS) in mRCC. We also studied the recently validated International Database Consortium (IDC) model in our data sets.